Solvay withdraws cilansetron NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Solvay has withdrawn its NDA for its irritable bowel syndrome agent cilansetron, the firm says Nov. 29. The company determined that "the amount of clinical work requested" as well as the potential IBS market for the 5-HT3 receptor antagonist suggested the company should focus on development of other compounds. Cilansetron was deemed "not approvable" March 23; FDA requested additional clinical trials to support an IBS indication for both women and men (Pharmaceutical Approvals Monthly April 2005, In Brief). Solvay said it is open to divesting cilansetron to another company...
You may also be interested in...
Solvay cilansetron "not approvable"
Solvay's irritable bowel syndrome therapy Calmactin (cilansetron) is "not approvable" March 23, one week ahead of the product's April 1 user fee date. FDA is requesting additional clinical trials to support an indication for treatment of IBS in both women and men. Solvay says it notified the agency March 30 of its intent to amend the cilansetron NDA. The decision follows the firm's February announcement that it no longer expected the Gastrointestinal Drugs Advisory Committee to review the 5-HT3 antagonist. The meeting was tentatively set for March 9 (1Pharmaceutical Approvals Monthly February 2005, p. 31)...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.